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Bioenergetic health index (BHI)The purpose of this study was to determine if mitochondrial dysfunction plays a role in diabetic nephropathy
(DN), a kidney diseasewhich affects N100million peopleworldwide and is a leading cause of renal failure despite
therapy. A cross-sectional study comparing DN with diabetes patients without kidney disease (DC) and healthy
controls (HCs); and renal mesangial cells (HMCs) grown in normal and high glucose, was carried out. Patients
with diabetes (DC) had increased circulating mitochondrial DNA (MtDNA), and HMCs increased their MtDNA
within 24 h of hyperglycaemia. The increased MtDNA content in DCs and HMCs was not functional as
transcription was unaltered/down-regulated, and MtDNA damage was present. MtDNA was increased in DC
compared to HC, conversely, patients with DN had lower MtDNA than DC. Hyperglycaemic HMCs had
fragmented mitochondria and TLR9 pathway activation, and in diabetic patients, mitophagy was reduced.
Despite MtDNA content and integrity changing within 4 days, hyperglycaemic HMCs had a normal bio-
energetic proﬁle until 8 days, after which mitochondrial metabolism was progressively impaired. Peripheral
blood mononuclear cells (PBMCs) from DN patients had reduced reserve capacity and maximal respiration,
loss of metabolic ﬂexibility and reduced Bioenergetic Health Index (BHI) compared to DC. Our data show that
MtDNA changes precede bioenergetic dysfunction and that patients with DN have impaired mitochondrial
metabolism compared to DC, leading us to propose that systemicmitochondrial dysfunction initiated by glucose
inducedMtDNA damage may be involved in the development of DN. Longitudinal studies are needed to deﬁne a
potential cause–effect relationship between changes in MtDNA and bioenergetics in DN.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetic nephropathy (DN) affects ~one-third of patients with dia-
betes and develops over a long period of clinical silence (Ritz and
Orth, 1999).With the epidemic rise in the incidence of diabetes current-
ly affecting more 350 million people, N100 million people are at risk of
DN and of these 30% are likely to progress to end stage renal failure de-
spite therapy (IDF, 2013;Wild et al., 2004). Therefore there is an urgent
need to understand the underlying mechanisms of damage in the
diabetic kidney in order to design novel therapeutics.
Clinical randomised studies such as the Diabetes Control and Com-
plications Trial and the Epidemiology of Diabetes Interventions and
Complication have shown that early intensive glycemic control reduces
risk, whereas prolonged hyperglycaemia can increase the long termodgkin Building, Guy's Campus,
K.
. This is an open access article underrisk of diabetic complications (Kilpatrick et al., 2009). Hyperglycaemia
is therefore accepted as amajor mediator of renal damage and activates
several complex and overlapping biochemical pathways resulting in
abnormal signalling in cells (Aronson, 2008; Brownlee, 2001). Diabetes
results in increased risk of numerous other complications which af-
fect major organs, including eyes (retinopathy), heart (diabetic car-
diomyopathy), blood vessel (peripheral vascular disease) and brain
(dementia) (Stratton et al., 2000). The multi-organ impact of diabetes
complications resembles mitochondrial genetic disease (Moraes et al.,
1991; Wallace, 1999) and suggests a systemic dysfunction in the body.
Mitochondria, cellular organelles in the cytosol of eukaryotic cells,
harbour their own circular DNA genome which is located outside the
nuclear genome, and require both mitochondrial and nuclear genome
encoded proteins to function. Mitochondria produce energy in the
form of ATP via oxidative phosphorylation (OXPHOS) (Wojtczak and
Zabłocki, 2008), therefore the number of mitochondria in a cell is relat-
ed to the energy requirements of the cell and can vary depending on
many factors such as the environment and redox balance of the cell
(Michel et al., 2012). Mitochondrial dysfunction can affect key cellularthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Baseline characteristics of healthy controls and diabetic patients with and without
nephropathy with MtDNA content.
Variable Healthy
controls
(HCs)
(n= 39)
Diabetic
controls
(DCs)
(n= 45)
Diabetic
nephropathy
(DN)
(n= 83)
Type of diabetes (T1D:T2D) NR 27:18 31:52
Age (years) 52 ± 25 49 ± 14 61 ± 14⁎⁎
Gender (female:male) 20:19 28:17 37:46
Diabetes duration (years) NR 22 ± 10 22 ± 13
BMI (kg/m2) 23 ± 4 27 ± 4# 30 ± 7⁎⁎##
HbA1c (%) ND 10 ± 9 8 ± 1
ACR (mg/mmol) ND 0.8 ± 0.6 18 ± 50⁎⁎
eGFR (ml min−1 1.73 m−2) ND 103 ± 21 66 ± 34⁎⁎
Systolic BP (mm Hg) ND 122 ± 12 133 ± 17⁎⁎
Diastolic BP (mm Hg) ND 72 ± 9 72 ± 9
Cholesterol (mmol/l) ND 4.4 ± 0.8 3.9 ± 0.9⁎
MtDNA content 34 ± 9 64 ± 75# 43 ± 52⁎⁎
MtDNA
(Median)
32 (35) 38 (469)# 26 (298)⁎⁎⁎
Data are means ± SD, except where otherwise indicated.
⁎ P b 0.05 compared with DC.
⁎⁎ P b 0.01 compared with DC.
⁎⁎⁎ P b 0.001 compared with DC.
# P b 0.05 compared with HC.
## P b 0.01 compared with HC.
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mitochondrial DNA (MtDNA) levels have been reported in a wide
range of human disease (Malik and Czajka, 2013).
We and others have reported changes in circulating MtDNA in
patients with DN (Lee et al., 2009;Malik et al., 2009). Reduced renal mi-
tochondrial function was postulated in a urinary metobolomics study
showing that mitochondrial metabolites were reduced in the urine of
DN patients (Sharma et al., 2013), however, it was suggested that the
basis for reduced mitochondrial content/function would be difﬁcult to
address in clinical samples. Therefore, despite some evidence that
mitochondrial dysfunctionmay be involved in DN, there is no direct ev-
idence in clinical samples and it is unclear whether measuring mito-
chondrial function in patients may have any translational potential.
Furthermore theunderlyingmolecularmechanisms are not understood.
If systemic mitochondrial dysfunction is associated with DN, then
we would predict systemic changes in the body which may be the
basis of renal microvascular complications in diabetes. Peripheral
blood mononuclear cells (PBMCs) from patients have been usedwidely
as surrogates and various parameters associatedwith DN can be detect-
ed in these cells (Hofmann et al., 1999; Ihm et al., 1997; Sourris et al.,
2010; Yi et al., 2014); our assumption is that PBMC mitochondria will
resemble systemic changes in the body and therefore will act as surro-
gate cells for kidney tissue. Recently, methodology formeasuring bioen-
ergetics in live fractionated blood cells have been developed and it has
been suggested that thesemay be utilised tomeasure oxygen consump-
tion rates (OCR) and extra cellular ﬂux analysis (ECAR) to indicate po-
tential mitochondrial dysfunction (Chacko et al., 2013) It has been
proposed that ECAR and OCR values can be combined using a formula
as a single value that deﬁnes an individual's bioenergetic health index
(BHI) which could be used as a prognostic/diagnostic indicator of met-
abolic stress.
In the current paper ourmajor aimwas to determine ifmitochondri-
al dysfunction can be detected in patients with DN and to elucidate the
potential mechanisms by which hyperglycaemia may affect renal
mitochondria. To expand our in-vivo observations we also utilised an
experimental in-vitro cell model system to examine the effects of
hyperglycaemia on renal mitochondria. We used primary human
mesangial cells (HMCs) as transformation can affect cellular bioenerget-
ics. Importantly, glomerular mesangial cells are a target of both meta-
bolic and haemodynamic perturbations in diabetes (Clarkson et al.,
2002; Murphy et al., 1999) and have been widely utilised as models of
DN.We therefore used PBMCs to examine systemic changes in diabetes
and HMCs to examine effect of diabetes on renal mitochondria.
2. Materials and Methods
2.1. Human Subjects
Patients were recruited between 2008 and 2014 with written in-
formed consent fromGuy's and St Thomas' hospital clinics under ethical
approval from the regional Research Ethics Committee (REC; ref num-
ber 07/H0806/120). The cross-sectional study adhered to the Ethical
Principles for Medical Research Involving Human Subjects, World
Medical Association Declaration of Helsinki. A random blood glucose
level of ≥11.1 or a fasting blood glucose level of ≥7 mmol/l was consid-
ered to be indicative of diabetes. Type 1 diabetes (T1D) and type 2
Diabetes (T2D) were deﬁned as follows: T1D: onset before age 35,
insulin therapy within 6 months of diagnosis and no breaks in insulin
therapy N6 months; T2D: onset after age 35, controlled by diet or
established oral hypoglycaemic treatment and/or insulin. Albumin/
creatinine ratio (ACR) was used to assess the level of albuminuria,
ACR b2.5 mg/mmol for men and ACR b3.5 mg/mmol for women, was
deﬁned as cut off for normo to microalbuminuria. Glomerular ﬁltration
rate (GFR) was assessed using the Modiﬁcation of Diet in Renal Disease
(MDRD) formula (Stoves et al., 2002). For controls without nephropa-
thy, we used patients with type 1 diabetes and type 2 diabetes with≥20 or ≥10 years of diabetes duration, respectively, without a history
of albuminuria, with normal renal function and normal blood pressure
(≤130/80 mm Hg) and taking no antihypertensive agents. HC (n =
39) with no history of the disease or current medication were recruited
with informed consent, andwere age and sexmatched with the patient
study group. Sample size was calculated from a pilot experiment using
Cohens d, which showed that n = 39 for each group was adequate to
power the MtDNA study. Table 1 shows the baseline characteristics of
subjects used in this study.
2.2. Primary Human Glomerular Mesangial Cells
Human kidneys unsuitable for transplantation or normal portion
from renal carcinoma were used as a source of primary human
mesangial cells (HMCs) which were cultured and characterised as pre-
viously described (Gruden et al., 1997; Thomas et al., 2000) and grown
in Dulbecco's Modiﬁed Eagle Medium (DMEM, Sigma Aldrich) supple-
mented with 10% FBS, ITS and antibiotics. Cells were seeded at an
equal density (1 × 105/well) in 6-well plates in DMEM containing
either 5 mM (normal, NG) or 25 mM (high, HG) glucose for varying
time points. 20 mM mannitol in 5 mM glucose DMEM was used as an
osmotic control in all experiments.
2.3. Real Time Quantitative PCR
Genomic DNA or RNA templates converted to cDNA were used for
real time qPCR using SYBR green (Qiagen) as previously described
(Shahni et al., 2013). All primer sequences used in the study are listed
(Table S3). Absolute quantiﬁcationwas carried out in the presence of di-
lution standards for each gene. ThemRNA copy numbers were calculat-
ed by dividing the mean values of target gene relative to the mean
values of β-actin (the most stably expressed gene), MtDNA copy
numbers were assessed as mitochondrial to nuclear gene ratio using
Beta-2 microglobulin (B2M) as the nuclear control (Malik et al., 2011).
2.4. Extracellular Flux Analysis
Extracellular ﬂux analysis is deﬁned as the measurement of cellular
bioenergetics (respiratory activity), based on the measurement of two
major energy pathways OXPHOS and glycolysis (Chacko et al., 2013;
Ferrick et al., 2008).
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human PBMCs s were assessed using the XFe96 Seahorse analyser
and XF cell mito stress test kit (Seahorse Biosciences). Oligomycin
(ATP synthase blocker) was used to measure ATP turnover and to de-
termine proton leak, the mitochondrial uncoupler — FCCP (carbonyl
cyanide 4-[triﬂuoromethoxy] phenylhydrazone) was used to mea-
sure maximum respiratory function (maximal OCR). Reserve capac-
ity was calculated as maximal OCR minus the basal respiration.
Rotenone (inhibitor of complex I) and Antimycin A (a blocker of
complex III), were used to measure non-mitochondrial respiration
(Brand and Nicholls, 2011; Dranka et al., 2011). The data generated
for OCR and ECAR in PBMCs were used to calculate the Bioenergetic
Health Index as described recently by Darley-Usmar group (Chacko
et al., 2014) using the BHI = log (reserve capacity) × (ATP-linked) /
(non-mitochondrial) × (proton leak).
2.5. Mitochondrial DNA Damage
DNA damage was quantiﬁed using the elongase method (Furda
et al., 2014) by comparing the relative ampliﬁcation of an 8.9 kb region
relative to a 127 bp region in the mitochondrial genome using speciﬁc
primers (Table S3). For the Surveyor Nuclease method (Bannwarth
et al., 2006), amplicon A was ampliﬁed (Table S3) and digested with
Surveyor nuclease. Gel electrophoresis was used in both methods to
detect MtDNA damage.
2.6. Measurement of ROS Production, Cell Viability and Apoptosis in Human
Mesangial Cells
Intracellular ROS in was measured using cell-permeant 2′,7′-
dichlorodihydroﬂuorescein diacetate (H2DCFDA) oxidation, cell viabili-
ty wasmeasured using CellTiter-Glo luminescence assay (Promega, UK)
in a microplate reader according to the manufacturer's instructions.
2.7. Assessment of Mitochondrial Network
Cells were grown in 96-well plates with clear bottoms, ﬁxed with
paraformaldehyde and visualized by staining with Mitotracker Red
(Invitrogen) according to the manufacturer's instructions. Cells were
viewed under Nikon Eclipse Ti-E Inverted Microscope, using CFI S Plan
Fluor ELWD 20×/0.45NA objective. The stained mitochondrial network
was assessed using ImageJ software (version 1.47q: National Institutes
of Health; www.rsb.info.nih.gov/ij) using an image-processing algo-
rithm (Koopman et al., 2005). Two different parameters, formfactor F
as a measure of degree of branching (calculated as a perimeter2 /
4Π ∗ area) aspect ratio AR (measure of mitochondria length) were
used to quantify mitochondrial morphology.
2.8. Statistics
Analysis was performed using GraphPad (GraphPad Software, Inc.)
and IBM SPSS for Windows software. The distribution of the data was
tested using the Kolmogorov–Smirnov test (graph pad) and histograms
in SPSS and parametric tests were used on raw or log transformed data.
For parametric analysis, groups were compared using t-test (2 groups)
or one way ANOVA with post-hoc Tukey's multiple comparison test
(N2 groups). For non-parametric analysis, groups were compared
using Mann–Whitney (2 groups) or Kruskal Wallis with Dunn's post-
hoc test with Bonferroni correction (N2 groups). Data are presented as
mean ± Standard error of the mean and as median for non-normally
distributed data.
2.9. Author Contributions
AC and SA generated the cell and human data respectively and are
joint ﬁrst authors, the study was conceived and designed by AM withthe help of LG and PJ, KP undertook MtDNA damage experiments, the
data analysis was undertaken by AC/SA/AM and evaluated by all
authors, the statistical analysiswas supported by FR, all authorswere in-
volved in the drafting and revision of the manuscript.
2.10. Funding
This work was partly funded by an EFSD/Janssen Programme for the
Study of the Role of the Kidney in Diabetes grant; AC and SA are sup-
ported by KCL PhD scholarships.
3. Results
3.1. Detection of Changes in Mitochondrial DNA and mRNAs in Blood
Samples From DN Patients
We ﬁrst set out to establish if we could conﬁrm and extend ours
and another study showing altered circulating MtDNA in DN patients
(Lee et al., 2009; Malik et al., 2009). Using small volumes of peripheral
blood, our assays comprised of measurement of MtDNA content,
and mRNA content of various mitochondrial-encoded and nuclear-
encoded mRNAs including genes encoding various mitochondrial
subunits, involved in biogenesis, fusion, ﬁssion and mitophagy. In
addition we assessed the integrity of MtDNA in these samples.
Using a cross-sectional study design, we compared 3 groups of sub-
jects: healthy controls (HCs, n = 39) were volunteers with no history
of any disease, diabetes controls (DCs, n = 45) comprised of patients
with ≥20 years diabetes duration, normal renal function and no history
of albuminuria, and diabetic nephropathy patients (DN, n = 83) with a
history of or current albuminuria (Table 1). The HC group were age and
sexmatched with the diabetes patients (Table S1) and had a lower BMI
(P b 0.05). The DN patients were older, had higher BMI, albumin/creat-
inine ratio (ACR), and systolic blood pressure and lower eGFR than DC.
We used both T1D and T2D patients in this study and analysed the
groups combined as hyperglycaemia plays a role in progression of
renal disease independently of the type of diabetes. Analysis of T1D
and T2D patients separately showed the same trends (Table S5).
MtDNA contentwas quantiﬁed as the ratio ofmitochondrial genome
to nuclear genome (Malik et al., 2011). DC had signiﬁcantly higher
MtDNA content compared to HC (P b 0.05) whereas the DN patients
had reducedMtDNA compared to DC (P b 0.001, Fig. 1A).We examined
if the decreased MtDNA in DN patients was a consequence of other pa-
rameters, as age, BMI, systolic blood pressure, eGFR and cholesterol,
were signiﬁcantly different between the DC and DN groups (Table 1).
After adjusting for these variables, stepwise binary regression analysis
showed that eGFR, systolic blood pressure and MtDNA levels remained
independently associated with DN (P = 0.009) however, age, BMI, and
cholesterol were no longer associatedwith DN. As reduced eGFR and el-
evated blood pressure are well known risk markers for DN (Alaveras
et al., 1997), our data strongly suggest that MtDNA levels represent a
new risk marker for DN and the associated increase in cardiovascular
morbidity and mortality of these patients.
To investigate if the changes in circulating MtDNA were accompa-
nied by altered transcription of mitochondrial mRNAs, we quantiﬁed
mitochondrial genome codedOXPHOS subunits; NADH oxidase subunit
VI (ND6), NADH oxidase subunit I (ND1) and cytochrome c oxidase sub-
unit 3 (COX3); and nuclear encoded mitochondrial mRNAs involved in
mitochondrial biogenesis (mitochondrial transcription factor A —
TFAM, Peroxisome proliferator-activated receptor gamma coactivator 1
alpha — PGC1A), ﬁssion (Dynamin-1-like protein — DRP1), fusion
(Mitofusin 1 and 2-MFN1 and MFN2, Optic atrophy 1 — OPA1) and
mitophagy (PTEN-induced putative kinase 1 — PINK1, parkin RBR E3
ubiquitin protein ligase — PARK2, Fig. 1B–L).
As the amount of MtDNA is known to be directly proportional to the
amount of mRNA (Hock and Kralli, 2009; Williams, 1986) we expected
to see changes in mitochondrial encoded mRNAs. However, despite
HC DC DN
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ations in mRNAs levels of mitochondrial encoded subunits (Fig. 1B–D)
or in most nuclear encoded mitochondrial mRNAs (Fig. 1F–J), suggest-
ing that the altered MtDNA levels are not functional. This idea is further
supported by the reduced TFAM levels (Fig. 1E), and a signiﬁcant reduc-
tion in mitophagy mRNAs in diabetes patients (Fig. 1K and L), suggest-
ing that removal of dysfunctional mitochondria is hampered. Despite
having higher MtDNA, DC patients have reduced TFAM compared to
HC, and despite having lower MtDNA, DN patients have higher TFAM
thanDC, supporting the idea that theMtDNAmay comprise of amixture
of functional and non-functional molecules. One possibility is that
MtDNA in these samples comprises of both intact and damaged/mutat-
edMtDNA i.e. there could be a level of heteroplasmy. The integrity of the
MtDNA was determined in a subset of patients, using two methods: a
PCR based “elongase method” (Furda et al., 2014) and the surveyor nu-
cleasemethod (Bannwarth et al., 2006). Using the elongasemethod, we
found that relative ampliﬁcation was lower in DC (84 ± 50) and DN
(85 ± 33) compared to HC (107 ± 37), but this difference was not
signiﬁcant (P N 0.05 Fig. 1M). Using surveyor nuclease, we detected mis-
matches in 5 out of 10 DN patients, but none in 10 HC patients (Fig. 1N).
Wewere unable to conﬁrm presence of mutations by Sanger sequencing.
As surveyor nuclease candetectN3%of heteroplasmywhereaswith Sang-
er sequencing detection levels are N20% (Bannwarth et al., 2006), our
data suggest that the DN patients have damaged MtDNA genomes pres-
ent at between 3% and 20% of the total MtDNA content.
3.2. Reduced Mitochondrial Metabolism in PBMCs From DN Patients
The data above showed that DN patients have reduced circulat-
ing MtDNA compared to DC patients and an increased level of
heteroplasmy. It is possible that this could affect cellular energy produc-
tion. Therefore we examined whether there is any difference in mito-
chondrial metabolism by determining the bioenergetic proﬁle of HC,
DC, andDNgroups. The baseline characteristics of this subset of patients
(Table S2) show similar trends to the whole study group (Table 1). We
used freshly puriﬁed PBMCs which were used for the assays within 2 h
of collection from patients. Basal, ATP-linked, maximal oxygen con-
sumption rate (OCR), reserve capacity and extracellular acidiﬁcation
rate (ECAR) were measured using a Seahorse XFe96 analyser. OCR, an
indicator of mitochondrial respiration, and ECAR, representative of
glycolysis, were normalised to the cell number of PBMCs from HC
(n = 10), DC (n = 14) and DN patients (n = 16).
Basal respiration (Fig. 2A), ATP-linked respiration (Fig. 2B), basal
glycolytic rate (Fig. 2E), proton leak and non-mitochondrial respiration
(data not shown) were similar in the 3 groups. However, both maximal
respiration and reserve capacity were signiﬁcantly reduced by ~40%
(P b 0.05) in DN patients (Fig. 2C and D). These data suggest that whilst
energy production capability under normal physiological conditions is
likely to be similar in the 3 groups, reduced reserve capacity and re-
duced maximal respiration in DN patients are suggestive of a compro-
mised response to stress.
3.3. Loss of Metabolic Flexibility in Diabetic Nephropathy
To investigate whether DN patients have a reduced response to
stress, we determined the effect of acute applied stress (Fig. 3A–G) in
PBMCs. Cell chambers were injected with high glucose (20 mM) and
the change in mitochondrial respiration was measured immediately.
Acute glucose loading had no impact on PBMCs from HC and DC, withFig. 1.Diabetes associated changes inmitochondrial DNA content andmitochondrial life cycle in
eral blood from HC (n = 39), DC (n = 45) and DN (n = 83) groups. Data are presented as bo
analysed using non-parametric Kruskal–Wallis test with Dunn'smultiple comparison test. (A)M
drial to nuclear (B2M) ratio. *P b 0.05, ***P b 0.001. (B–L) Quantitative analysis ofmitochondrial
plate and real time qPCRwas used to quantify mRNA copy numbers relative to 1000 copies of re
method inHC (n= 10),DC (n= 14) andDN(n= 16), data are presented asmean ± SEM. (N)
(+). Digested bands in DN patients are illustrated with red arrows.a trend for slight but non-signiﬁcant reduction in basal, ATP-linked,
maximal respiration and reserve capacity, showing that these cells are
able to handle acute stress (Fig. 3A–D). In contrast, PBMCs from DN
patients were sensitive to acute glucose loading (Fig. 3E and F), as al-
though therewas no signiﬁcant change in basal and ATP-linked respira-
tion, both maximal respiration and reserve capacity were signiﬁcantly
decreased (P b 0.05). Maximal respiration (119.8 ± 39.7) decreased
40% (83.7± 29.1, P=0.05) and reserve capacity (74.4± 30) decreased
~50% (40.2 ± 0.7, P = 0.04) after acute load in DN patients (n = 8).
There was no signiﬁcant difference in basal ECAR between the three
groups in high glucose and normal glucose (Fig. 3G).
As this data shows that DN patients have a compromised metabolic
response, with a reduced maximal respiration and reserve capacity
compared to HC and DC, we sought to determine if there is any transla-
tional potential in identifying DN patients using the bioenergetics re-
sponse of PBMCs. Therefore, the bioenergetics data (Fig. 2 A–D) were
used to calculate the Bioenergetic Health Index (BHI) as described re-
cently by the Darley-Usmar group (Chacko et al., 2014) (Fig. 2F). The
mean (+/−SD) BHI value for DN patients (3.0 ± 0.4, n = 12, P =
0.01) was signiﬁcantly lower than DC (3.4 ± 0.2, n = 5) (Fig. 2F,
Table S4).
3.4. Hyperglycaemia-induced Changes inMitochondrial DNA andmRNAs in
Human Renal Glomerular Mesangial Cells
The data presented above suggested that in PBMCs fromDNpatients
there may be a dis-connect between MtDNA levels and mitochondrial
mRNA levels. As PBMCs may be reﬂective of systemic changes in the
body (Rudkowska et al., 2011), we wanted to determine if diabetes
could affect renal mitochondria. To investigate this we used primary
glomerular mesangial cells (HMCs) and examined the effect of
hyperglycaemia on their mitochondria. Growth of HMCs in 25 mM glu-
cose (HG) for 4 days resulted in a ~2.5-fold increase in cellular MtDNA
content (717 ± 157) compared to cells cultured in 5 mM glucose
(NG) (280 ± 53, n = 4, P b 0.01, Fig. 4A). A time course experiment
showed that MtDNA content began to increase within 24 h of incuba-
tion in HG, and this increase was statistically signiﬁcant (P = 0.02)
after 72 h (Fig. 4B).
To examine whether increased MtDNA content after 4 days of
growth inHGwas accompanied by increased transcription ofmitochon-
drial mRNAs, we quantiﬁed mitochondrial genome encoded OXPHOS
subunits, and nuclear encoded mitochondrial mRNAs involved in mito-
chondrial biogenesis, ﬁssion, fusion and mitophagy.
Surprisingly, there was a more than 50% reduction in ND6 and COX3
mRNA in HG (Fig. 4C and E, P b 0.01), and no signiﬁcant change was ob-
served in ND1 mRNA (Fig. 4D, P N 0.05), suggesting that increased
MtDNA did not result in increasedmitochondrial genome transcription.
TFAMmRNAwas signiﬁcantly increased by ~140% (Fig. 4F, P b 0.05), but
the levels of the remaining mRNAs did not change in HG (P N 0.05,
Fig. 4G–M). No changes were observed at the protein level when mito-
chondrial respiratory complexes I–V were measured via Western blot
(data not shown).
3.5. Functional Consequences of Hyperglycaemia in Kidney Cells
Since nuclear encoded mRNAs involved in the mitochondrial life
cycle did not respond to hyperglycaemia in the time frame in which
the MtDNA increase was seen; we examined intracellular reactive
oxygen species (ROS) (measured using DCF ﬂuorescence which is ancirculating cells. DNA and RNAwere isolated from 0.1 ml and 1 ml respectively of periph-
x plots (except for M) with whiskers showing median, quartiles and range which were
tDNA content. Real time qPCRwas carried out to determineMtDNA content asmitochon-
(mitomRNA) and nuclear encodedmRNAs. RNAwas converted to cDNA and used as tem-
ference geneβ-actin.*P b 0.05, **P b 0.01. (M)MtDNAdamage assessed using the elongase
Representative agarose gels showing ampliconA (−) and after surveyor nuclease digestion
FHC
DC
DN
Fig. 2.Dysfunctionalmetabolic response in live peripheral bloodmononuclear cells (PBMCs) frompatientswith diabetic nephropathy. PBMCs fromHC (n=10), DC (n=14) andDN(n=
16)were isolated, seeded at 3 × 105 cells/well, and the Seahorse XFe96 extracellular ﬂux analyser was used tomeasure oxygen consumption rate (OCR) and extracellular acidiﬁcation rate
(ECAR). Data presented asmean± SEM and analysed by one-way ANOVAwith Tukey's test. (A) Basal respiration rate. (B) ATP-linked respiration after ATP synthase blocker (oligomycin)
injection. (C) Maximal (uncoupled) respiration rate measured after the FCCP injection *P b 0.05. (D) Reserve capacity, measured as a difference between maximal and basal respiration,
*P b 0.05. (E) Basal ECAR (glycolysis). (F) BHI calculated for HC (n = 8), DC (n = 5) and DN (n = 12) groups, *P b 0.05.
504 A. Czajka et al. / EBioMedicine 2 (2015) 499–512assay of generalised oxidative stress and not mitochondrial speciﬁc,
Kalyanaraman et al., 2012), cell viability, MtDNA damage, and mito-
chondrialmorphology in order to elucidate the underlyingmechanisms.
There was a signiﬁcant increase in ROS in HMCs grown in HG
(Fig. 5A, P b 0.001). In parallel to the increasedROS, cell viabilitywas sig-
niﬁcantly reduced inHMCs grown inHG(Fig. 5B). As the increase in ROS
was paralleled with the increase in MtDNA (Fig. 4A) and a reduction in
MtDNA transcription (Fig. 4C–E), we speculated that ROSmight damage
the MtDNA, and that the damaged MtDNA may then activateinﬂammation via the TLR9 pathway (Oka et al., 2012). MtDNA damage
was signiﬁcantly increased in cells grown in HG at 4 days (Fig. 5C,
P b 0.05), and at the same time both NF-κB and MYD88 mRNAs were
signiﬁcantly increased (Fig. 5D and E, P b 0.001, P b 0.01), suggesting
activation of the TLR9 pathway.
MitoTracker Red staining was used to examine the effect of HG on
the mitochondrial network in HMCs. Images were acquired at different
time points (Fig. 5F). In cells grown in NG, the mitochondrial network
was seen as a mixture of elongated and connected mitochondria
HC
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Fig. 3. The loss of metabolic ﬂexibility in diabetic nephropathy patients. Live PBMCs fromHC (n= 4), DC (n= 4) and DN (n= 8) were isolated, seeded at 3 × 105 cells/well and analysed
using theMito Stress Test (Seahorse) in the Seahorse XFe96 analyser. Oxygen consumption rate (OCR) and extracellular acidiﬁcation rate (ECAR) were determined without (−, red) and
with (+, blue) acute glucose load. Data are expressed as mean± SEM, n= 12–20 assay replicates per sample (A, C, D). Independent Student's t-test. (A) Mean OCR values in HC samples.
(B) Representative example from a single HC sample. (C) Mean OCR values DC samples. (D) Representative example from a single DC patient. (E) Mean OCR in DN patients.
(F) Representative example from a single DN patient. (G) Mean ECAR from HC, DC and DN.
505A. Czajka et al. / EBioMedicine 2 (2015) 499–512(Fig. 5F top panel), and no signiﬁcant changes were observed during the
duration of the experiment (data not shown). When cells were grown in
HG, their mitochondria became more rounded and fragmented (Fig. 5F).
Plotting the values for bothmitochondrial length/width (aspect ratio AR)
versus degree of branching (formfactor F) showed a progressive reduc-
tion in both parameters with increased time of HG exposure (Fig. 5F
right panel). The aspect ratio was signiﬁcantly down regulated in cells
exposed to HG, and appeared to change within 24 h (Fig. 5G, P b 0.01).
This change became highly signiﬁcant after a longer time of exposure,
with the appearance of more mitochondria of a rounded shape (Fig. 5G,
P b 0.001). Formfactor F values were also signiﬁcantly decreased,following 24 h of exposure to HG with the lowest values at day 8
(Fig. 5H, P b 0.001). These results suggest that incubation in HG leads to
increased oxidative stress, MtDNA damage, reduced cellular viability, mi-
tochondrial fragmentation and loss ofmitochondrial network connection
indicating mitochondrial dysfunction.
3.6. Reduced Metabolism in Kidney Cells Grown in High Glucose
To assess the effect of continued hyperglycaemia on mitochondrial
bioenergetics in renal cells, HMCs were incubated in NG and HG for 4,
8 and 12 days, and basal, ATP-linked, maximal OCR, reserve capacity
5 mM glucose (NG)
25 mM glucose (HG)
A B
C D
F G
H
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J
Fig. 4. Glucose-induced changes in mitochondrial DNA content and mitochondrial gene transcription in kidney cells. HMCs were cultured in 5 mM glucose (NG) and 25mM glucose (HG) for
4 days and used to prepare DNA and RNA. Real-time qPCRwas carried out to determineMtDNA content using the DNA as template, and expressed as themitochondrial to the nuclear genome
ratio. FormRNAquantiﬁcation theRNAwas converted to cDNAandused as template,mRNAcopynumbers for eachgeneweredetermined relative to1000 copies of referencegeneβ-actin. Data
are presented asmean± SEM, n N 3 independent experiments. Independent Student's t-test. (A) Quantitativemeasurement of theMtDNA content in HMCs after 4 days, **P b 0.01. (B)MtDNA
content in HMCs measured every 24 h, *P b 0.05, **P b 0.01. (C–M) Quantitative analysis of mitochondrial (mito mRNA) and nuclear encoded mRNAs in HMCs, *P b 0.05, **P b 0.01.
Fig. 5. Functional consequences of hyperglycaemia in kidney cells. HMCswere cultured in 5 mMglucose (NG) and 25 mMglucose (HG) for the times shown. (A–B)ROSproduction and cell
viability shown as a % of control. Data are presented as mean ± SEM, n = 17–21 observations. Non-parametric Mann Whitney test, **P b 0.01, ***P b 0.001. (C) Quantitative analysis of
MtDNA damage assessed using the elongase method. Data are presented as mean± SEM, n= 2, 5–6 observations/experiment. Mann–Whitney test, *P b 0.05. (D, E) mRNA expression
analysis of NF-kB, MYD88 in HMCs. RNA was converted to cDNA and used as template, mRNA copy numbers for each gene were determined relative to 1000 copies of reference gene
β-actin. Data are presented as mean ± SEM, n = 3. Independent Student's t-test, **P b 0.01, ***P b 0.001. (F) Mitochondrial morphology in HMCs exposed to high glucose. Mitochondria
were labelled with MitoTracker Red CMXRos and images were captured at magniﬁcation ×20. Representative images of each condition shown in left panel. Mitochondrial length (aspect
ratio—AR)was plotted againstmitochondrial degree of branching (formfactor F) and shown on the right panel as scatter plots. Scale bar, 50 μm. (G–H)Quantitative analysis of aspect ratio
AR and formfactor F shown as a % of the control. Data are presented as mean ± SEM, n = 2, N14 cells/experiment. Non-parametric Kruskal–Wallis test with Dunn's multiple comparison
test, **P b 0.01, ***P b 0.001.
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508 A. Czajka et al. / EBioMedicine 2 (2015) 499–512and ECAR were measured using a Seahorse XFe96 analyser (Fig. 6A–H).
OCR and ECARwere both normalised to the protein content as HMCs are
growing cells, and presented as pmolesO2/min/μg protein.We could detect no differences in the bioenergetic proﬁle of cells in-
cubated in HG for 4 days, as basal, ATP-linked, maximal respiration and
basal glycolytic rate were similar between cells grown in NG and HG
509A. Czajka et al. / EBioMedicine 2 (2015) 499–512(Fig. 6A–F). Cells exposed to HG for 8 days had similar basal and ATP-
linked respiration and the basal glycolytic rate, but had a reduced max-
imal respiration (P b 0.05, Fig. 6A–E and G). After 12 days of incubation
in HG, cells showed signiﬁcantly reduced basal, ATP-linked, maximal
respiration and basal glycolytic rate (P b 0.05, Fig. 6A–E and H). No
changeswere observed in the proton leak andnon-mitochondrial respi-
ration for any of the time points (data not shown). The reserve capacity
was unchanged at 4 days, but was reduced in cells grown in HG after 8
and 12 days (P b 0.05, Fig. 6D and F–H). Mitochondrial respiration in
cells incubated in HG was independent of osmolarity or culture time
(data not shown). Comparison of basal respiration ratewith basal glyco-
lytic rate showed no difference at 4 and 8 days in HG (Fig. 6I and J).
However, after 12 days, the cells grown in HG had reduced OCR and
ECAR (P b 0.05) which shows that they have shifted to a less metaboli-
cally active state (Fig. 6K).4. Discussion
Diabetes increases the risk of multi-organ complications affecting
various cell types and is a major cause of blindness, renal failure, and
cardiovascular disease (Gordin et al., 2012; He and King, 2004). Our
study suggests that systemic mitochondrial dysfunction and glucose in-
duced changes in MtDNA parallel diabetic kidney disease. The role of
MtDNA mutations in mitochondrial genetic disease (Hudson et al.,
2014; Niaudet, 1998; Tuppen et al., 2010; Wallace and Chalkia, 2013)
and of MtDNA as an inﬂammatory molecule (Collins et al., 2004;
Zhang et al., 2010) has been demonstrated. Speciﬁc MtDNA mutations
can lead to diabetes and kidney disease in patients with mitochondrial
genetic disease (D'Aco et al., 2013; Mazzaccara et al., 2012; Seidowsky
et al., 2013), suggesting that acquired MtDNA damage may play a role
in DN. We present novel evidence showing that glucose induced
increase in MtDNA in renal cells precede mitochondrial dysfunction,
suggesting a novel cascade of events contributing to mitochondrial
dysfunction in patients with DN (Fig. 7).
Wewere interested in comparing DC patients, who had a long dura-
tion of diabetes but did not develop kidney disease, with the DN group,
who had developed kidney disease, in order to determine if susceptibil-
ity for the development of diabetic kidney disease may involve
mitochondrial dysfunction. Our data shows that it is possible using
PCR based assays to detect differences in MtDNA and mitochondrial
mRNAs between diabetes patients who develop kidney disease and
those that don't. We used extracellular ﬂux analysis, as previously
described (Ferrick et al., 2008), to measure cellular respiration, and
showed, using live PBMCs, that DN patients have a diminished bioener-
getic response. We also converted the bioenergetics data to the
single value “Bioenergetic Health Index (BHI)” which has recently
been proposed as a new biomarker for assessing patient health with
both prognostic and diagnostic value (Chacko et al., 2014), and we
found that DNpatients had signiﬁcantly reduced BHI. To our knowledge
this is the ﬁrst report demonstrating altered BHI in patients, supporting
the hypothesis that mitochondrial dysfunction is involved in DN. In fact,
there have been very few studies reporting metabolic function in live
PBMCs and none speciﬁcally in diabetic complications (Hartman et al.,
2014;Maynard et al., 2013).We have detected a clear difference inmet-
abolic function between the DC and DN group and our data suggests
that inability to cope with energy demand due to MtDNA damage
could be a key factor in the progression of DN.Fig. 6. Reducedmetabolism in kidney cells grown in high glucose. HMCs were grown in 5 mM g
plated at a density of 3.5 × 104 cells/well one day prior to the experiment. The Seahorse XFe96
tracellular acidiﬁcation rate (ECAR), all data were normalised to the protein content and sho
***P b 0.001. (B) ATP-linked OCR after oligomycin injection. (C) Maximal (uncoupled) OCR afte
pacity, measured as a difference between maximal and basal respiration rates, *P b 0.05, ***P
showingmitochondrial respiration in HMCs cultured in NG, HG and osmotic control (Man) at 4
basal ECAR inHMCs cultured inNG, HGand osmotic control (Man) at 4, 8 and 12 days respective
an arrow. Data are presented as mean ± SEM, n = 6–8 replicates for 2 independent experimeTo establish whether hyperglycaemia can affect renal mitochondria
and contribute to mitochondrial dysfunction, we used primary glomer-
ular mesangial cells, widely used as an experimental model of DN
(Clarkson et al., 2002; Thomas et al., 2000). The data derived from the
HMC experiments supports the hypothesis that glucose can lead to
alterations in MtDNA and mitochondrial function in renal cells and
may be considered as representative of an early stage in diabetes.
Exposure of HMCs to hyperglycaemia led to changes in mitochondrial
morphology and increased MtDNA levels with 24 h, after 4 days there
was reduced transcription of the mitochondrial genome, increased
ROS and MtDNA damage, and activation of the NF-κB pathway, and
after 8–12 day HMCs displayed reduced mitochondrial metabolism.
These results suggest that the observed similar defect seen in PBMCs
occur at a systemic level and could be the cause of the changes we see
in mitochondrial parameters in PBMCs from DN patients. Circulating
MtDNA levels have been previously reported to be increased in diabetes
but there have been contradictory reports in DN (Lee et al., 2009;
Malik et al., 2009), possibly due to the fact that earlier studies used
mitochondrial primers which may amplify nuclear pseudogenes
with high homology to MtDNA (Malik and Czajka, 2013; Malik
et al., 2011). In the current study, using unique primers and a proto-
col designed for accurate MtDNA quantiﬁcation from blood (Ajaz
et al., 2014) we found that DC patients had signiﬁcantly higher levels
of circulating MtDNA compared to HC. Several mitochondrial- and
nuclear-encoded mitochondrial mRNAs remained unchanged, apart
from reduced TFAM, PINK1 and PARK2, suggesting that the increased
MtDNA in DC patients may not be fully functional, and that
mitophagy may be impaired. The inhibition of mitophagy and the
presence of damaged MtDNA are very likely to lead to a decrease in
mitochondrial quality. The DN patients had signiﬁcantly reduced
MtDNA compared to DC. Binary regression analysis showed that
eGFR, A/C ratio, and MtDNA levels were independently associated
with DN. As eGFR and A/C ratio are well established risk markers of
DN, our data suggests that theMtDNA changes could be a riskmarker
for DN; prospective studies will have to answer this question in the
future.
A key ﬁnding of our study is the demonstration that exposure to HG
leads to a rapid increase in mesangial cell MtDNA, accompanied by un-
changing/decreased transcription of mitochondrial encoded mRNAs
and little change in nuclear encoded mitochondrial mRNAs in renal
cells. The amount of MtDNA is known to be directly proportional to
the amount of mitochondrial encoded mRNAs (Hock and Kralli, 2009;
Williams, 1986) however in our study increased MtDNA levels in pa-
tients (Fig 1A) are not accompanied by increased mitochondrial
encoded mRNAs (Fig. 1B–D), we see the same trend in cells, where
the mitochondrial encoded mRNAs are reduced (Fig. 4C–E) whereas
theMtDNA in increased (Fig. 4A). As the function ofMtDNA is to encode
mitochondrial mRNAs, we deduce that the increased MtDNA in not
functional. The only exception is the glucose induced up-regulation of
TFAM mRNA, which has been previously reported (Choi et al., 2004).
Our observation is suggestive of a disconnect between the increase in
MtDNA and mitochondrial transcription/translation. A similar discon-
nect was reported in a study investigating the mechanisms of insulin
resistance in muscle, with increased MtDNA but not increased mito-
chondrial content in myotubes (Aguer et al., 2013). Increased MtDNA
in cultured cells was reported in response to hydrogen peroxide
induced oxidative stress (Lee and Wei, 2005). HG induced ROS may in-
hibit mitochondrial biogenesis, as has been shown in other systemslucose (NG, open bars) and 25mM glucose (HG, solid bars) for 4, 8 and 12 days, and then
extracellular ﬂux analyser was used to measure oxygen consumption rate (OCR) and ex-
wn as pmoles/min/ug protein. (A) Quantitative measurement of the basal OCR in HMCs,
r FCCP injection, *P b 0.05, ***P b 0.001. (D) Quantitative measurement of the reserve ca-
b 0.001. (E) Basal ECAR (glycolysis), *P b 0.05. (F–H) Representative mito stress test runs
, 8 and 12 days respectively. (I–K) Representative analysis of the basal OCR plotted against
ly. HMCsgrown inHG for 12 days had lowerOCR/ECAR ratio,metabolic shift is indicatedby
nts. Independent Student's t-test.
Fig. 7. Early glucose induced changes in mitochondria may lead to diabetic nephropathy: a schematic diagramwith each box referring to key ﬁndings of this paper given in brackets. The
early changes refer to data obtained from cultured renal cells. The late changes refer to data obtained from PBMCs fromHC, DC and DNpatients. The evidence supporting this schematic in
the paper: hyperglycaemia leads to increasedMtDNA content (Fig. 4A), alteredmitochondrial morphology (Fig. 5, F–H), increased intracellular reactive oxygen species (ROS Fig. 5A), mi-
tochondrial DNA damage (Fig. 5C), cellular damage measured as apoptosis/viability (Fig. 5B), and inﬂammation (Fig. 5, D and E) as early changes in cells. These changes precede and are
followedby reducedOCR (basal,maximal, ATP-linked), reserve capacity and ECAR (Fig. 6, A–E). These changesmay result in damagedmitochondria, blockedmitochondrial biogenesis and
an energy deﬁcit. The long term consequences of such changes could be as shown in the bottom panel. In DC patients these changes are seen as an increase inMtDNA (Fig. 1A) and normal
metabolism (Fig. 2, A–E) however DN patients have decreasedMtDNA (Fig. 1A) accompaniedwith a dysfunctionalmetabolic response (Fig. 2A–E) resulting in reduced BHI (Fig. 2F). There
is evidence of reduced mitophagy in both DC and DN patients (Fig. 1, K and L).
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tered mitochondrial transcription and translation which we observe.
The increase in MtDNA in these conditions could be a compensatory re-
sponse to the impairment of transcription.
We measured cellular respiration in HMCs and found that oxidative
metabolism can cope for several days of high stress conditions
and continues to provide energy. Cells started to display altered mor-
phology within a few hours of exposure to HGwith mitochondrial frag-
mentation,whichmay be part of the initiation of an adaptive biogenesis
programme to increaseMtDNA content.Whilst glucose inducedMtDNA
increase was evident within 24 h, cells showed no detectable perturba-
tion in their metabolic proﬁle at this time point. Some changes were
seen after 8 days, however it was only after 12 days of culture that sig-
niﬁcantly reduced ECAR and OCRwere observed. To our knowledge this
is the ﬁrst report of themetabolic response of HMCs, although previous-
ly ameeting report onmousemesangial cells showed similar proﬁles to
ours (Chacko et al., 2010a). Our data agreewith a study using rat retinal
endothelial cellswhere growth inHG for 6 days led to reduced basal and
maximal respiration, however unlike our study where ECAR was de-
creased, they found increased ECAR (Trudeau et al., 2010). The reduced
ECAR in our cells is suggestive of an energy deﬁcit and may be a conse-
quence of a ROS induced glycolytic block (Colussi et al., 2000). This idea
is supported by our ﬁnding of HG induced ROS in our cells. The impor-
tance of mitochondrial ROS in oxidative stress in the kidney is well
established, andmitochondrial targeted antioxidants ameliorate certain
markers of renal damage (Chacko et al., 2010b). Here we show that theincreased ROS is accompanied by increased MtDNA damage and NF-κB
andMYD88mRNAs. Like bacterial DNA, MtDNA is un-methylated and
can initiate immune responses via the intracellular Toll like receptor
(TLR) 9 (Higginbotham et al., 2002). The inﬂammatory properties of
MtDNA (Collins et al., 2004; Zhang et al., 2010) and disruption of the
normal degradation of MtDNA in the cytosol of cardiomyocytes was
shown to cause TLR9-mediated inﬂammation leading to a heart failure
in a mouse model (Oka et al., 2012). It is well established that chronic
inﬂammation is a keymediator in diabetic complications but the under-
lying mechanisms have not been elucidated (Navarro-Gonzalez et al.,
2011). Our data in HMCs of increased MtDNA content, ROS, MtDNA
damage, and up-regulation of MYD88 and NF-κB support the idea of
MtDNA induced activation of the inﬂammatory TLR9 pathway in these
cells and are suggestive of a novelmechanism leading to chronic inﬂam-
mation in DN.
MtDNA is usually present in multiple identical copies in the cells, but
the location of MtDNA close to the electron transport chain renders it
more susceptible to ROS induced damage andmutations. In diabetes pa-
tients, MtDNA may be exposed to hyperglycaemia induced oxidative
stress (Singh et al., 2011) resulting in random mutations in the mito-
chondrial genome leading to heteroplasmy, the presence of normal and
mutated MtDNA in the same cell. The damaged MtDNA in such cases
would only have an impact once it reached a thresholdwhere the normal
non-mutated MtDNA is no longer able to compensate for mitochondrial
dysfunction (Chinnery, 2002). It has recently been demonstrated that
MtDNA heteroplasmic mutations are associated with widely spread
511A. Czajka et al. / EBioMedicine 2 (2015) 499–512chronic diseases, including atherosclerosis and cancer (Sobenin et al.,
2014; Ye et al., 2014). We used two methods to detect MtDNA damage,
both of which suggest that MtDNA from diabetes samples shows in-
creased damage, with heteroplasmy being detected only in DN samples.
Furthermore, HMCs showed a signiﬁcant increase in MtDNA damage
after 4 days of growth in hyperglycaemic conditions, suggesting
MtDNA damage in HMCs could play a role in the subsequent bioenerget-
ic deﬁcit observed in these cells after 8 and 12 days of hyperglycaemia.
The combination of the data presented in this paper paint a picture of
severely compromisedmitochondria in patients with DN. These patients
have reducedMtDNA in circulation, with increasedMtDNA damage, and
decreased mitophagy, the functional impact of these changes is the re-
duced metabolic ﬂexibility of these cells. Furthermore if we assume
that the PBMCs are representative of systemic changes in the body,
then it could be predicted that kidney cells in the DN patients will
show a similar compromised response, which could play a major role
in progression of pathology. Our results support a recent metabolomics
study showing that patients with DN have reduced mitochondrial me-
tabolites in urine (Sharma et al., 2013) and we propose that DN could
be viewed as a disease of acquired mitochondrial dysfunction.
In conclusion, we have shown that metabolic dysfunction can be
detected in peripheral blood samples of patients with DN. We have
also shown using renal cells in-vitro that hyperglycaemia affects
mitochondria, with MtDNA levels changing before other indicators of
mitochondrial dysfunction. Our data suggests that the BHI formula can
indicate mitochondrial dysfunction in live PBMCs from patients, and
therefore could be developed into a non-invasive translational measure
of mitochondrial function. It is of importance to determine if the
changes we observe in clinical samples precede the onset of DN, and
therefore longitudinal studies should be carried out to determine this.
The potential of regular and routine monitoring of MtDNA content,
integrity and BHI as indicators of DN should be further evaluated.
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